False positive Coombs test
Using Co-amoxiclav may cause a non-specific binding of antibody and protein (IgG and albumin respectively) due to the presence of clavulanic acid which may result in a false positive Coombs test.
Use of anticoagulants with Co-amoxiclav
Patients taking anticoagulants
with Co-amoxiclav are at increased risk when using this medicine. These patients may experience increased bleeding
time (prothrombin time). Careful monitoring and dose adjustment of anticoagulants are recommended in patients using Co-amoxiclav.
Patients with reduced urination
Patients with reduced urination are at increased risk when using Co-amoxiclav. Using Co-amoxiclav in patients with reduced urine output may cause cloudiness due to crystals
in the urine (crystalluria) when taken parenterally. Appropriate fluid intake and excretion of urine are recommended in patients. A regular checkup is necessary for patients with bladder catheters.
Urine glucose test
Using Co-amoxiclav may cause false positive results during a urine glucose test. Use enzymatic glucose oxidase methods for testing of the presence of glucose in urine.
Patients with blisters and red, scaly rash with bumps under the skin (acute generalized exanthemous pustulosis)
The patients with these skin conditions are at increased risk when using this medicine. Using Co-amoxiclav may cause fever
with red, scaly rash and bumps under the skin (feverish generalized erythema) along with pus-containing blisters (pustula) in patients with acute generalized exanthemous pustulosis. Patients should stop or avoid taking Co-amoxiclav on the occurrence of feverish generalized erythema with pustules.
Development of drug-resistant bacteria
Using Co-amoxiclav in the improper diagnosis of bacterial infection may cause the development of resistance in bacteria for the drug.
Abnormal functioning of the kidney
Patients with abnormal functioning of the kidney or taking higher doses of Co-amoxiclav are at an increased risk when using Co-amoxiclav. Use of Co-amoxiclav in these patients may cause convulsions. Dose adjustment is recommended in such patients.
Patients with amoxicillin sensitive bacterial (amoxicillin-susceptible organism) infection
Patients with amoxicillin-susceptible organism are at increased risk when using Co-amoxiclav. Co-amoxiclav may cause an infection in such patients. Changing Co-amoxiclav therapy to only amoxicillin therapy should be recommended after proper clinical guidance.
Patients taking allopurinol
Such patients are at an increased risk when using Co-amoxiclav. These patients may develop an allergic skin reaction.
Excessive growth of non-sensitive bacteria (overgrowth of non-susceptible organisms)
Patients taking Co-amoxiclav are at an increased risk. Prolong use of Co-amoxiclav treatment may develop excessive growth of non-sensitive bacteria against medicines.
Allergic to Co-amoxiclav
Patients with a history of allergic reactions to penicillins, cephalosporins, allergens or receiving beta-lactam antibacterials are at an increased risk when using Co-amoxiclav. Such patients may experience life-threatening allergic reactions (anaphylactic) reactions. Before starting the treatment with Co-amoxiclav, careful analysis is required regarding previous allergic reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, discontinue the use of Co-amoxiclav.
Abnormal functioning of the liver
Such patients are at an increased risk when using this medicine. These patients may experience conditions such as abnormal functioning of the liver, inflammation of the liver (hepatitis
), decrease in bile flow from liver (cholestatic jaundice
) and fatal conditions due to liver failure. Precaution in dose adjustment and regular monitoring of liver function is recommended in patients with abnormal functioning of the liver.
Clostridium difficile associated diarrhea
The patients using antibacterial drugs are at increased risk while using this medicine. The use of Co-amoxiclav may cause mild diarrhea
to possibly fatal colitis
. Antibacterial agents alter the organisms present in the colon causing overgrowth of the Clostridium difficile bacteria. If Clostridium difficile associated diarrhea (CDAD) occurs discontinue the use of Co-amoxiclav. The suitable treatment for treatment of this kind of diarrhea includes an appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment, and surgical evaluation as clinically indicated.
Patients with mononucleosis (an infectious condition caused by virus)
Such patients are at an increased risk when using Co-amoxiclav. Co-amoxiclav cause redness of the skin (erythematous skin rash) in patients with mononucleosis
. Such patients should not use this medicine.
The patients who are using Co-amoxiclav are at an increased risk of occurrence of superinfections caused by bacterial or fungal pathogens. If superinfection occurs, discontinue the use of Co-amoxiclav.